Are new pillars emerging in DLBCL?
It’s time to take a short break from the immunometabolism mini-series and turn our attention to aggressive lymphomas such as diffuse large B cell lymphomas (DLBCL).
This week heralded the latest AACR virtual meeting on Advances in Lymphoma in conjunction with iCML. There were plenty of science focused talks to listen to and learn from, including new developments in oncogenic targeting.
What if we can learn from what the patients underlying biology can teach us in terms of more rationally designed clinical trials?
We know these are diverse and heterogeneous tumours, but this doesn’t mean we can’t take a more precision medicine approach to treating patients. What can we learn from early trial readouts and genetic analyses?
It turns out, the answer is quite a bit and more information might be available at the forthcoming ASH meeting, so let’s look at what we can piece together from the available data now…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging on aggressive lymphomas, subscribers can log-in or you can click to gain access to BSB Premium Content.
John P. Leonard, MD is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell in New York. He’s a Lymphoma specialist.
Dr John Leonard at ASH16
Like many hematologists, he’s embraced Twitter as way to share his expertise with others in the hematology community. You can follow him at @JohnPLeonardMD.
Over the last couple of years prior to the ASH annual meeting, Dr Leonard has highlighted 10 lymphoma abstracts that caught his attention. You can tell he gets excellent social media pickup by the fact he’s even generated a hashtag to make them easy to find: #Leonardlist and other hematologists generate conversations around his eagerly awaited picks:
In case you missed them on Twitter, and in the spirit of David Letterman, Dr Leonard took me through this year’s #LeonardList and thoughtfully explained in detail why each selection made the cut… for oncology watchers, the why is often more important than the what.
Subscribers can login to read more